MindWalk Holdings (HYFT) Current Taxes (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Current Taxes of $59090.0 for Q2 2026, down 82.3% year-over-year from $333796.1 in Q2 2025, and down 75.0% quarter-over-quarter from $236346.9 in Q1 2026.
MindWalk Holdings (HYFT) Current Taxes (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Current Taxes for 7 consecutive years, with $59090.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Taxes fell 82.3% year-over-year to $59090.0; the TTM figure through Apr 2026 stood at $59090.0 (down 82.3% YoY), while the FY2026 annual figure was $59090.0, down 82.67% from the prior year.
- Current Taxes fell to $59090.0 in Q2 2026 per HYFT's latest filing, from $236346.9 in the prior quarter.
- Across five years, Current Taxes topped out at $464568.0 in Q1 2022 and bottomed at $1478.1 in Q2 2023.
- Historically, Current Taxes has averaged $230091.2 across 5 years, with a median of $236346.9 in 2026.
- Annual changes were most pronounced in 2023 — Current Taxes slumped 99.55% — and 2024, when it soared 27492.8%.
- MindWalk Holdings' Current Taxes stood at $23339.8 in 2022, then surged by 1685.3% to $416684.0 in 2023, then slumped by 54.83% to $188198.2 in 2024, then jumped by 62.79% to $306373.6 in 2025, then slumped by 80.71% to $59090.0 in 2026.
- Business Quant data shows HYFT's Current Taxes at $59090.0 in Q2 2026, $236346.9 in Q1 2026, and $306373.6 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 49.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 76.32 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 59,089.99 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 74.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 59,089.99 |
| Jan 31, 2026 | 236,346.86 |
| Oct 31, 2025 | 306,373.58 |
| Apr 30, 2025 | 333,796.13 |
| Jan 31, 2025 | 142,294.22 |
| Oct 31, 2024 | 188,198.20 |
| Jul 31, 2024 | 408,974.71 |
| Apr 30, 2024 | 407,848.71 |
| Jan 31, 2024 | 155,341.51 |
| Oct 31, 2023 | 416,684.05 |
| Jul 31, 2023 | 285,446.65 |
| Apr 30, 2023 | 1,478.10 |
| Jan 31, 2023 | 77,846.41 |
| Oct 31, 2022 | 23,339.76 |
| Jul 31, 2022 | 72,310.02 |
| Apr 30, 2022 | 331,613.16 |
| Jan 31, 2022 | 464,568.00 |
| Oct 31, 2021 | 322,152.30 |
| Jul 31, 2021 | 45,583.05 |
| Apr 30, 2021 | 258,941.00 |